Results 101 to 110 of about 9,527 (158)
One-Year Substantia Nigra R 2 * Changes across Parkinson's Disease Stages. [PDF]
Mov DisordCoussediere C, Pereira B, Devos D, Lehéricy S, Peran P, Durand E, Chassain C, Houeto JL, Benatru I, Colin O, Rascol O, Ory-Magne F, Brefel-Courbon C, Maindreville AD, Vidailhet M, Corvol JC, Frismand S, Schmitt E, Defebvre L, Carriere N, Meissner WG, Boraud T, Remy P, Moro E, Thobois S, Geny C, Bonny JM, Durif F, Marques A, MPI‐R2* study group. +29 moreeuropepmc +1 more sourceClinical responses to trastuzumab deruxtecan in molecularly defined ependymoma. [PDF]
NPJ Precis OncolGonzalez Castro LN, Wu YC, Lin JR, Santiago-Ribeiro MJ, Laurenge A, Carpentier A, Coy S, Lin NU, Mokhtari K, Ligon KL, Touat M, Santagata S. +11 moreeuropepmc +1 more sourceDiagnostic Value of the Kappa Free Light Chain Index to Distinguish MOGAD, NMOSD, and MS. [PDF]
NeurologyTournier A, Gavoille A, Pique J, Levraut M, Micoud E, Maillart E, Audoin B, Demortiere S, Boutiere C, Ayrignac X, Boucraut J, Jentzer A, Ciron J, Bost C, Collongues N, Deschamps R, Cohen M, Seitz-Polski B, Thouvenot E, Squalli S, Maréchal D, Branger P, Ahle G, Zephir H, Vukusic S, Klapczynski F, Laplaud DA, Giannesini C, Mélé N, Drouet T, Sterlin D, Marignier R. +31 moreeuropepmc +1 more source